Introduction
Uterine smooth muscle tumors are extremely common and most of them are benign. Histologically almost all leiomyomas are easily recognized for being of smooth muscle origin and also as a benign tumor. 1 These tumors are the most common uterine neoplasms whereas the malignant counterpart constitutes approximately 1% of uterine malignancies. 2, 3 Leiomyoma with bizarre nuclei is a term that has been used for smooth muscle tumors with focal or diffusely distributed multinucleated giant cells in which no coagulative tumor cell necrosis and no increased mitotic activity is seen 4 (Figure 1 C&F). Przybora introduced the term "leiomyosarcoma in situ" for these neoplasms in 1961 for being considerable concern about the giant cell component, 5 however, "Symplastic" and "atypical" leiomyoma are frequently used synonyms for these type of tumors. Although results of numerous studies with long time follow up indicate for uneventful clinical course for leiomyoma with bizarre nuclei, [6] [7] [8] in a more recent study, the Stanford investigators reported 46 additional cases of atypical leiomyomas, which 4 of them recurred.
9
Likewise considerable controversy has surrounded the nature of atypical nuclei in LBNs. For example some investigators consider these nuclei "malignant" whereas the other consider as a "degenerative change" occurred in benign cells. 10 In fact it is extremely difficult to distinguish the degenerative nuclei from truly atypical and malignant cells with confidence on light microscopic examination.
11
This study is conducted for identifying of immunohistochemical profile of the atypical nuclei in LBN and compares them with benign and malignant counterparts.
In addition we identified the immunohistochemical differences between various types of uterine smooth muscle tumors and tried to clarify to how degree the current terminologies and classifications are supported by molecular findings.
Materials and Methods
After approval from the institutional review board and ethical committe at Tabriz University of Medical Sciences (Tabriz, Iran), 32 cases of uterine smooth muscle tumors were selected for this study and analysis. 
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Abstract
Purpose:
To assess the immunohistochemical profile of the atypical nuclei in leiomyoma with bizarre nuclei and compare with benign and malignant counterparts. Methods: 26 cases of uterine smooth muscle tumors including 12 leiomyosarcoma(LMS), 10 leiomyoma with bizarre nuclei (LBN) and 4 smooth muscle tumor with uncertain malignant potential (STUMP) were selected using whole tissue sections for this study and analysis. Six cases of ordinary leiomyoma were included as benign control group. All representative section were stained for P53, Ki67, estrogen receptor and progestrone receptor. Analysis was carried out using SPSS 16.0 for windows software. Diagnosis of LMS, STUMP, LBN and conventional leiomyoma was based on criteria published earlier.
12,13
Briefly coagulative tumor cell necrosis, mitotic count more than 10 / 10 HPF and nuclear atypia were used as essential histologic criteria for diagnosis and classifying uterine smooth muscle tumors. A tumor with 2 of these 3 criteria is often a malignant tumor to warrant a diagnosis of leiomyosarcoma. STUMP was used in any condition in which we encountered with unusual combination of these histologic criteria that didn't fit for diagnosis of leiomyosarcoma.
11 Similarly we used leiomyoma with bizarre nuclei in cases with focal or multifocal collections of atypical cells showing large, bizarre and multilobulated nuclei in association with hyperchromasia. The mitotic count should be on average less than 2-3 /10 HPF. A representative block was selected from each case. Briefly we used MIB1(Dako, Copenhaghen, Denmark ), P53 monoclonal antibody (clone DO-7, ready to useDako), Estrogen Receptor a monoclonal antibody (clone1D5, Ready to use-Dako) and Progesterone Receptor monoclonal antibody (PgR 636, Ready to useDako) for detecting of Ki 67 antigen, P53, ER and PR respectively. Only nuclear staining was considered as positive in all marker staining. For P53, diffuse (>75% of cell population) and strong nuclear staining was considered as positive. Ki 67 score was counted on minimum 500 cells at HPF which containing representative sections of tumor and calculated as fraction of positive cells to total number of cells in percentage. ER and PR positivity was scored using the so-called "Allred Score". 14 Data analysis was performed using SPSS 16.0/ win for windows computer program. Chi-square or Fishers Exact test were used to compare the qualitative variables when appropriate. Statistical significance level was considered at P<0.05.
Results
6 out of 12 cases of LMS showed strong and diffuse nuclear staining with p53 antibody (50%) while only 1 case of LBNs (11%) and none of STUMPs and leiomyomas was positive for p53 ( Table 1 ). The percentage of positive nuclei in ki67 stained slides was 0.85% in LBNs and 7% in STUMPs while 14.92% of nuclei in leiomyosarcomas showed positive nuclear staining with Ki67 (P<0.001). None of cells in 6 ordinary leiomyoms showed positive reaction for this marker (Table 1 ). Regard to steroid hormone receptors a significant loosing trend was found in these receptors from benign toward malignant tumors through LBN and STUMP cases (Table 1) . It should be mentioned that some differences regard to number of cases in tables are related to missing of representative foci in repeated microscopic section in process of IHC staining.
Advanced Pharmaceutical Bulletin, 2015, 5(Suppl 1), 683-687 15, 16 and presence of these cells has provoked considerable concern among pathologists in some of the otherwise conventional leiomyomas. Regard to biologic behavior, in a large comprehensive series studied by Downes and Hart, 12 none of their 24 cases showed recurrence or metastasis in long term follow up although only four of the 24 cases treated with myomectomy. In contrast in another study 4 of 46 leiomyoma with bizarre nuclei recurred and none of them including the recurrent cases showed mitotic rate above 3/10 HPF. 9 For resolving this dilemma some molecular studies tried to declare the biologic nature of these atypical cells and compare the immunohistochemical findings between malignant, atypical and benign smooth muscle cells. For example in a study on nine cases of symplastic uterine leiomyomas, Sun and Mittal found no significant difference in expression of P53, ER and PR immunostaining between atypical and non-atypical cells except for Ki67 which significantly was higher in atypical cells. 10 In contrast Sung et al. found p53 expression in 5 of 13 cases of leiomyoma with bizarre nuclei and ki67 expression in less than 5% of atypical nuclei with one recurrent case.
7
In contrast with the last study our results revealed a distinctive difference between malignant cells in leiomyosarcoma and other groups regard to expression of p53 ( Figure 1A-C) . Six cases from 12 leiomyosarcoma (50%) in this study showed positive immunoreactivity, while none of our STUMPs and only one case of LBNs showed positive reaction. These results are in line with recently published series of nine LBNs in which no statistically significant difference was found between non-atypical and atypical cells in relation to p53 staining.
10 Likewise our findings are in line with O'Nell et al. in which expression of p53 was found in only 3/11 symplastic leiomyoma. 17 The significant difference in number of Ki-67 positive cells between leiomyosarcoma cases as a group and STUMP, LBN and leiomyoma as another group (P<0.05) and increasing rate of Ki-67 positivity ( Figure 1D-F) from conventional leiomyoma to frankly malignant leiomyosarcoma through LBN and STUMP in our study may indicate for a biologic potential of recurrence in LBN and STUMP cases which has been found in some of the follow up studies although the proliferative index in our LBNs was lower than the other reports. Our immunohistochemical findings indicate that the application of current microscopic criteria for diagnosis and nomenclature of these tumors is usefull although the number of cases were relatively limited in this study. Other limitations in our research was absence of follow up results because many cases were new patients. Other investigations with higher number of cases with diagnostic value instruction and follow up studies may be useful for achievement of more significant results.
Conclusion
In conclusion our molecular findings showed that P53 immunostaining as a part of IHC panel may be used for histopathologic diagnosis of problematic uterine smooth muscle tumors and probably loss of inhibitory function of wild type p53 gene in leiomyosarcoma is an essential event that does not occur in atypical leiomyomas. In addition presence of higher proliferative index in leiomyosarcoma cases may be indicative for biologic mechanism of highly aggressive clinical course that seen in this group of uterine smooth muscle tumors.
